A pharmaceutical composition for the treatment and/or prophylaxis of diseases caused by type I hypersensitivity reactions consisting essentially of Glicophosphopeptical, or pure Nigella Sativa seeds, in a concentration which stimulate Th1 lymphocytes and selectively switch-off the eosinophilic airway inflammationA method of treatment of allergy using Th1 stimulating agents, to be administered to a mammal such as human in need of such treatment in a shot of 5 days only, resulted in significant decrease in symptom score started day 3, and in sputum eosinophils by day 14, followed by long-term clinical remission of a mean of 6 months.The BCG-like Th1 stimulation is also used in treating diseases in which the body defensive mechanism is a Cell Mediated Immunity, including viral infections, as but not limited to influenza and common cold, Chronic and recurrent urinary tract infection, pelvic inflammatory diseases as neuroimmune appendicitis, cancer, crohns disease and facial palsy.

 
Web www.patentalert.com

< Uses of DNA-PK

> Cytokine inhibitors

> Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors

~ 00545